Overview A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 Status: Completed Trial end date: 2012-01-01 Target enrollment: Participant gender: Summary This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease. Phase: Phase 3 Details Lead Sponsor: IMPAX Laboratories, Inc.Impax Laboratories, LLCTreatments: CarbidopaCarbidopa, levodopa drug combinationEntacaponeLevodopa